Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemia

Blood

Volumn 111, Issue 9, 2008, Pages 4752-4763

  Roccaro, Aldo M ^a,b   Leleu, Xavier ^a   Sacco, Antonio ^a   Jia, Xiaoying ^a   Melhem, Molly ^a   Moreau, Anne Sophie ^a   Ngo, Hai T ^a   Runnels, Judith ^a   Azab, Abdelkareem ^a   Azab, Feda ^a   Burwick, Nicholas ^a   Farag, Mena ^a   Treon, Steven P ^a   Palladino, Michael A ^c   Hideshima, Teru ^a   Chauhan, Dharminder ^a   Anderson, Kenneth C ^a   Ghobrial, Irene M ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Nereus Pharmaceuticals Inc   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SALINOSPORAMIDE A; TRANSCRIPTION FACTOR RELA; BORONIC ACID DERIVATIVE; LACTONE; PROTEASOME; PYRAZINE DERIVATIVE; PYRROLE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYME CELL; PRIORITY JOURNAL; WALDENSTROEM MACROGLOBULINEMIA; CELL ADHESION; CELL CULTURE; CELL DEATH; CELL MOTION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; ENZYMOLOGY; PATHOLOGY;

BORONIC ACIDS; CELL ADHESION; CELL DEATH; CELL MOVEMENT; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; HUMANS; LACTONES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; PYRROLES; WALDENSTROM MACROGLOBULINEMIA;

EID: 44649148060     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-120972     Document Type: Article

References (43)

1. Treon SP, Gertz MA. Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia. Blood. 2006;107:3442-3446.
2. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4:679-685.
3. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110-115.
4. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29:3-9.
5. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5:417-421.
6. Panwalkar A, Verstovsek S, Giles F. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer. 2004;100:1578-1589.
7. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431-436.
8. Hatzimichael EC, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL. Serum levels of IL-6 and its soluble receptor (slL-6R) in Waldenstrom's macroglobulinemia. Eur J Haematol. 2001;66:1-6.
9. Chauhan D, Uchiyama H, Akbarali Y. etal. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87:1104-1112.
10. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647.
11. Heilbig G, Christopherson KW, Bhat-Nakshatri P, etal. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem. 2003;278:21631-21638.
12. O'Dea EL, Barken D, Peralta RQ, et al. A homeostatic model of IkappaB metabolism to control constitutive NF-kappaB activity. Mol Syst Biol. 2007; 3:111.
13. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007;110:4417-4426.
14. Hideshima T Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.
15. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of Bortezomib in relapsed/refractory Waldenstrom's Macroglobulinemia: results of WMCTG trial 03-248. Clin Cancer Res. 2007;13:3320-3325.
16. Feling RH, Buchanan GO, Mincer TJ, etal. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed Engl. 2003;42:355-357.
17. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8:407-419.
18. Santos DHA, Tournilhac O, Leleu X, et al. Establishment of a Waldenstrom's Macroglobulinemia cell line (BCWM. 1) with productive in vivo engraftment in SCID-hu mice. Clin Exp Hematol. 2007;35:1366-1375.
19. HideshimaT, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053-62.
20. Dillon CP, Sandy P, Nencioni A, Kissler S, Rubinson DA, Van Parijs L. Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu Rev Physiol. 2005;67:147-173.
21. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003;33:401-406.
22. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom's Macroglobulinemia. Blood. 2007;109:4964-4972.
23. Ahn KS, Sethi G, Aggarwal BB. Embelin, an inhibitor of X chromosome-linked inhibitor-ofapoptosis protein, blocks nuclear factor-kappaB (NF-kappaB} signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol. 2007;71:209-219.
24. Lightcap ES, McCormackTA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000; 46:673-683.
25. Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12) dependent migration and homing in multiple myeloma. Blood. 2007;109:2708-2717.
26. Sipkins DA, Wei X, Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435:969-973.
27. Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003;63:6174-6177.
28. Zaman F, Menendez-Benito V, Eriksson E, et al. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. Cancer Res. 2007;67:10078-10086.
29. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907-4916.
30. Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistiinc cytotoxicity in multiple myeloma. Blood. 2008;111:1654-1664.
31. Chauhan D, Li G, Hideshima T, et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003;102:3379-3386.
32. Monaco C. Evangelos A, Serafim K, et al. Canonical pathway of nuclear factor κB activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A. 2004;101:5634-5639.
33. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006;108:4178-4186.
34. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006;42:1564-1573.
35. Landowski TH, Olashaw NE, Agrawal D, Dalton W. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kB (RelB/p50) in myeloma cells. Oncogene. 2003; 22:2417-2421.
36. Gutierrez NC, Ocio EM, de Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia. 2007;21:541-549.
37. Hatzimichael EC, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL. Serum levels of IL-6 and its soluble receptor (slL-6R) in Waldenstrom's macroglobulinemia. Eur J Haematol. 2001;66:1-6.
38. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood. 2004;104:3712-3721.
39. Okamura M, Yamaji S, Nagashima Y, et al. Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol. 2007;38:1081-1091.
40. Huang D, Khoe M, Befekadu M, et al. Focal adhesion kinase mediates cell survival via NF-kB and ERK signaling pathways. Am J Physiol Cell Physiol. 2007;292:C1339-C1352.
41. Moreau AS, Jia X, Ngo H, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood. 2007;109:4964-4972.
42. Miller C, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 2007;110:267-277.
43. Hatjiharissi E, leontovich A, Timm M, et al. Proteomic analysis of Waldenstrom macroglobulinemia. Cancer Res. 2007;67:3777-3784.